AU2023228703A1 - Oral pclx-001 in the treatment of human cancer - Google Patents

Oral pclx-001 in the treatment of human cancer Download PDF

Info

Publication number
AU2023228703A1
AU2023228703A1 AU2023228703A AU2023228703A AU2023228703A1 AU 2023228703 A1 AU2023228703 A1 AU 2023228703A1 AU 2023228703 A AU2023228703 A AU 2023228703A AU 2023228703 A AU2023228703 A AU 2023228703A AU 2023228703 A1 AU2023228703 A1 AU 2023228703A1
Authority
AU
Australia
Prior art keywords
pclx
cancer
oral dosage
hours
per day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023228703A
Other languages
English (en)
Inventor
Neal Maynard DAVIES
John Robert MACKEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pacylex Pharmaceuticals Inc
Original Assignee
Pacylex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pacylex Pharmaceuticals Inc filed Critical Pacylex Pharmaceuticals Inc
Publication of AU2023228703A1 publication Critical patent/AU2023228703A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2023228703A 2022-03-03 2023-03-03 Oral pclx-001 in the treatment of human cancer Pending AU2023228703A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263316153P 2022-03-03 2022-03-03
US63/316,153 2022-03-03
PCT/CA2023/050281 WO2023164776A1 (en) 2022-03-03 2023-03-03 Oral pclx-001 in the treatment of human cancer

Publications (1)

Publication Number Publication Date
AU2023228703A1 true AU2023228703A1 (en) 2024-09-12

Family

ID=87882761

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023228703A Pending AU2023228703A1 (en) 2022-03-03 2023-03-03 Oral pclx-001 in the treatment of human cancer

Country Status (10)

Country Link
US (1) US20250161299A1 (https=)
EP (1) EP4486344A4 (https=)
JP (1) JP2025507923A (https=)
KR (1) KR20240155234A (https=)
CN (1) CN118829428A (https=)
AU (1) AU2023228703A1 (https=)
CA (1) CA3244234A1 (https=)
IL (1) IL314984A (https=)
MX (1) MX2024010584A (https=)
WO (1) WO2023164776A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025050208A1 (en) * 2023-09-05 2025-03-13 Pacylex Pharmaceuticals Inc. Oral pclx-001 in the treatment of human cancer
CN120361006A (zh) * 2025-05-19 2025-07-25 上海交通大学医学院附属第九人民医院 Nmt1抑制剂及其在制备实体瘤治疗药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110974967B (zh) * 2012-10-30 2023-11-07 厄尔莱克斯制药公司 合成致死与癌症的治疗
JP7539760B2 (ja) * 2015-07-17 2024-08-26 パシレックス・ファーマシューティカルズ・インコーポレイテッド Ｎｍｔ２の後成的なサイレンシング
GB201820660D0 (en) * 2018-12-19 2019-01-30 Imperial Innovations Ltd Cancer treatments
MX2023004341A (es) * 2020-10-20 2023-05-24 Pacylex Pharmaceuticals Inc Uso de inhibidores de n-miristoil transferasa (nmt) en el tratamiento del cancer, trastornos autoinmunes y trastornos inflamatorios.

Also Published As

Publication number Publication date
JP2025507923A (ja) 2025-03-21
CN118829428A (zh) 2024-10-22
WO2023164776A1 (en) 2023-09-07
MX2024010584A (es) 2024-09-06
KR20240155234A (ko) 2024-10-28
CA3244234A1 (en) 2023-09-07
EP4486344A4 (en) 2026-03-04
IL314984A (en) 2024-10-01
EP4486344A1 (en) 2025-01-08
US20250161299A1 (en) 2025-05-22

Similar Documents

Publication Publication Date Title
TWI831916B (zh) 包含tno155和瑞博西尼之藥物組合
Jin et al. Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer
CN112566660B (zh) 具有braf突变的癌症的组合疗法
US20250161299A1 (en) Oral pclx-001 in the treatment of human cancer
EP3638233B1 (en) Tinostamustine for use in treating ovarian cancer
WO2022271923A1 (en) Erk1/2 and kras g12c inhibitors combination therapy
US11957662B2 (en) Treatments with nirogacestat
US12213958B2 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
KR20140040728A (ko) Pi3k 억제제 화합물을 사용한 중피종 치료 방법
US11951096B2 (en) Treatments with nirogacestat
EP4119557A1 (en) Pharmaceutical combination comprising pyridino[1,2-a]pyrimidinone compound
WO2025050208A1 (en) Oral pclx-001 in the treatment of human cancer
US20250025446A1 (en) Treatments with nirogacestat
AU2012308993A1 (en) Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients
JP2022532597A (ja) Ｃｈｋ１阻害剤を使用してがんを治療する方法
KR20230031443A (ko) 벤즈이미다졸 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
WO2014031856A1 (en) Combination therapy using pi3 kinase and braf inhibitors
CN115120732B (zh) 一种喹唑啉化合物的药物组合物及其制备方法
WO2026019787A1 (en) Methods of treating merkel cell carcinoma with tryptophan hydroxylase inhibitors
WO2025188928A1 (en) Administration of low-dose thiostrepton for treating cancer
WO2022271939A1 (en) Erk1/2 and cdk4/6 inhibitors combination therapy
TW202444376A (zh) 治療癌症之方法
HK1190636A (en) Methods of treating mesothelioma with a pi3k inhibitor compound
AU2002245927A1 (en) Method for treatment of cancer and compositions for use therein
JP2000503994A (ja) 結腸腫瘍を抑制する方法